Evaluating Omitting of Internal Mammary Irradiation Among Early Stage Intermediate Risk (N1) Breast Cancer

NARecruitingINTERVENTIONAL
Enrollment

214

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

October 30, 2025

Study Completion Date

October 30, 2030

Conditions
Breast Cancer
Interventions
RADIATION

omit of IMI group

clincial high risk breast (≥2 risk factors)patients with 18-gene low risk an indication for regional nodal irradiation will received 2 Gy for 25 fractions to chest wall or whole breast and supraclavicular lymph nodes irradiation and sequential tumor bed boost of 2 Gy for 5 fractions following breast conserving surgery.

RADIATION

IMI group

clincial high risk breast (≥2 risk factors)patients with 18-gene low risk an indication for regional nodal irradiation will received 2 Gy for 25 fractions to chest wall or whole breast and supraclavicular lymph nodes irradiation and sequential tumor bed boost of 2 Gy for 5 fractions following breast conserving surgery.

Trial Locations (1)

200025

RECRUITING

Ruijin Hospital, Shanghai jiaotong univestigy school of medicine, Shanghai

All Listed Sponsors
lead

Ruijin Hospital

OTHER